JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Menasche, P.
Right arrow Articles by Piwnica, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menasche, P.
Right arrow Articles by Piwnica, A.

The Journal of Thoracic and Cardiovascular Surgery, Vol 100, 13-21, Copyright © 1990 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

A promising approach for improving the recovery of heart transplants. Prevention of free radical injury through iron chelation by deferoxamine

P Menasche, C Grousset, C Mouas and A Piwnica
Service de Chirurgie Cardio-Vasculaire, Hopital Lariboisiere, Paris, France.

Iron catalysis is involved in the generation of the highly cytotoxic hydroxyl radical and in the chain reactions of subsequent lipid peroxidation that lead to irreversible membrane damage. Assuming that ischemically stored heart transplants may incur free radical injury at the time of reoxygenation, we assessed the effects of the iron chelator deferoxamine in 70 isolated isovolumic buffer-perfused rat hearts subjected to the following protocol: cardioplegic arrest; cold (2 degrees C) storage for 5 hours; global ischemia at 15 degrees C for 1 hour, intended to simulate the implantation procedure; and normothermic reperfusion for 1 additional hour. During poststorage ischemic arrest, the following techniques of myocardial protection were evaluated: hypothermia alone; high-pressure (60 cm H2O) cardioplegia given at 0, 30, and 55 minutes of arrest; low-pressure (30 cm H2O) cardioplegia given at 0 and 55 minutes of arrest; and low-pressure (30 cm H2O) cardioplegia only given at 55 minutes of arrest. Treated hearts had deferoxamine (6 mumol) added to the cardioplegic solution used throughout the experimental time course. Further, in the treated group subjected to the protocol of single cardioplegic delivery at end ischemia, deferoxamine was given both in the cardioplegic reperfusate and in the Krebs buffer over the 15 initial minutes of reflow. Based on comparisons of postreperfusion ventricular pressure development, maximal rate of rise of ventricular pressure, left ventricular compliance, and coronary flow, the best myocardial protection was afforded by deferoxamine given as an additive to single-dose cardioplegic solution at the end of arrest and to the reperfusate during the initial phase of reoxygenation. As the drug has no inotropic effect, its protective action is most likely related to a decrease in catalytic iron available for free radical production and lipid peroxidation. These results support the hypothesis that oxidative damage may contribute to donor heart failure and demonstrate that this form of damage can be efficiently acted upon by iron chelation. The clinical relevance of these data stems from the fact that deferoxamine is available for human use and might become an effective means of improving donor heart preservation in the setting of clinical heart transplantation.


This article has been cited by other articles:


Home page
J. Thorac. Cardiovasc. Surg.Home page
Y. Tanoue, S. Morita, Y. Ochiai, M. Hisahara, M. Masuda, Y. Kawachi, R. Tominaga, and H. Yasui
INHIBITION OF LIPID PEROXIDATION WITH THE LAZAROID U74500A ATTENUATES ISCHEMIA-REPERFUSION INJURY IN A CANINE ORTHOTOPIC HEART TRANSPLANTATION MODEL
J. Thorac. Cardiovasc. Surg., October 1, 1996; 112(4): 1017 - 1026.
[Abstract] [Full Text]


Home page
Ann. Thorac. Surg.Home page
J. S. Ikonomidis, V. Rao, R. D. Weisel, N. Hayashida, and T. Shirai
Myocardial Protection for Coronary Bypass Grafting: The Toronto Hospital Perspective
Ann. Thorac. Surg., September 1, 1995; 60(3): 824 - 832.
[Abstract] [Full Text]


Home page
PerfusionHome page
Shu Tao, G. Calza, F. Lerzo, A. Virgone, N. Camassa, G. Panizzon, L. Brunelli, R. Moretti, P. Grasso, G. Ghiggeri, et al.
Activation of the intracellular glutathione system by oxydative stress during cardiopulmonary bypass and myocardial perfusion
Perfusion, January 1, 1995; 10(1): 45 - 50.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. Drossos, A. Lazou, P. Panagopoulos, and S. Westaby
Deferoxamine Cardioplegia Reduces Superoxide Radical Production in Human Myocardium
Ann. Thorac. Surg., January 1, 1995; 59(1): 169 - 172.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1990 by The American Association for Thoracic Surgery.